Amgen Inc.

Exelixis, Inc.

Bristol-myers Squibb Compnay

Joon Won Jeong

Daniel A Erlanson

Jeffrey Iwig

Christopher Michael Tegley

Wei Xu

T G Murali Dhar

John M Nuss

Kevin Chao Yang

Ryan D White

Victor J Cee

Yong Wang

Elena S Koltun

Brian Alan Lanman

Ryan Paul Wurz

James William Leahy

Vu Van Ma

Lynne Canne Bannen

Youngsook Shin

Russell Graceffa

Patrick C Kearney

Sunghoon Ma

Xiao Mei Zheng

Jesse M McFarland

John R Butler

Mohamed Ibrahim

Yongwei Wu

Gary Lee Lewis

Abhisek Banerjee

Byung Gyu Kim

Robin Tammie Noguchi

Raymond V Fucini

Henry William Beecroft Johnson

Shuyan Yi

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof. 

N-cyano-7-azanorbornane derivatives and uses thereof

Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

KRAS G12C inhibitors and methods of using the same

Described are RORy modulators of the formula (I), and N-oxides thereof, and pharmaceutically acceptable salts thereof, and solvates and hydrates thereof, wherein R, R, R, R, R, R, R, x, y, L, G, Z, the bond denoted by 'q', the ring system denoted by 'A' and the ring system denoted by &#x201c;B&#x201d; are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORy activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORy activity, for example, autoimmune and/or inflammatory disorders. 

ROR&#x3b3; modulators

This disclosure relates to sphingosine-1-phosphate (S1P) receptor antagonists, compositions comprising the S1P receptor antagonists and methods for using and processes for making the S1P receptor antagonists. In particular, this disclosure relates to sphingosine-1-phosphate 1 (S1P1) receptor antagonists, compositions comprising the S1P1 receptor antagonist and methods for using the S1P1 receptor antagonist, such as in the treatment of cancer, and processes for making the S1P1 receptor antagonists.

Acetanilide sphingosine-1-phosphate receptor antagonists

Growing community of inventors

Belmont, CA, United States of America

Joon Won Jeong